SG11202003893UA - Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy - Google Patents

Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy

Info

Publication number
SG11202003893UA
SG11202003893UA SG11202003893UA SG11202003893UA SG11202003893UA SG 11202003893U A SG11202003893U A SG 11202003893UA SG 11202003893U A SG11202003893U A SG 11202003893UA SG 11202003893U A SG11202003893U A SG 11202003893UA SG 11202003893U A SG11202003893U A SG 11202003893UA
Authority
SG
Singapore
Prior art keywords
monospecific
cancer therapy
immune checkpoint
bispecific proteins
checkpoint regulation
Prior art date
Application number
SG11202003893UA
Other languages
English (en)
Inventor
Jhong-Jhe You
Ching-Hsuan Hsu
Po-Lin Huang
Hung-Tsai Kan
Ting-Yi Chang
Hsin-Ta Hsieh
Jeng-Horng Her
Original Assignee
Ap Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ap Biosciences Inc filed Critical Ap Biosciences Inc
Publication of SG11202003893UA publication Critical patent/SG11202003893UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/75—Agonist effect on antigen
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
SG11202003893UA 2017-12-29 2018-12-28 Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy SG11202003893UA (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762611543P 2017-12-29 2017-12-29
PCT/US2018/067868 WO2019133817A1 (en) 2017-12-29 2018-12-28 Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy

Publications (1)

Publication Number Publication Date
SG11202003893UA true SG11202003893UA (en) 2020-05-28

Family

ID=67068142

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202003893UA SG11202003893UA (en) 2017-12-29 2018-12-28 Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy

Country Status (13)

Country Link
US (2) US11643470B2 (ko)
EP (2) EP4268848A3 (ko)
JP (2) JP7362614B2 (ko)
KR (1) KR102452246B1 (ko)
CN (2) CN111344019B (ko)
AU (1) AU2018394939B2 (ko)
BR (1) BR112020013133A2 (ko)
CA (1) CA3082036A1 (ko)
ES (1) ES2966569T3 (ko)
MY (1) MY195411A (ko)
SG (1) SG11202003893UA (ko)
TW (2) TW202116811A (ko)
WO (1) WO2019133817A1 (ko)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR102469248B1 (ko) * 2018-02-28 2022-11-22 에이피 바이오사이언시스, 아이엔씨. 표적치료법을 위한 체크포인트 억제력을 갖는 이중작용성 단백질
WO2021073611A1 (zh) * 2019-10-17 2021-04-22 江苏康宁杰瑞生物制药有限公司 Ox40/pd-l1双特异性抗体
WO2021097800A1 (en) * 2019-11-22 2021-05-27 Abl Bio Inc. Anti-pd-l1/anti-b7-h3 multispecific antibodies and uses thereof
CN112830972A (zh) * 2019-11-25 2021-05-25 中山康方生物医药有限公司 抗pd-1-抗vegfa的双特异性抗体、其药物组合物及其用途
TW202334203A (zh) * 2021-11-19 2023-09-01 德商皮里斯製藥有限公司 新穎的ox40及pd-l1特異性融合蛋白

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5541297A (en) 1988-04-01 1996-07-30 Immunomedics, Inc. Therapeutic conjugates of toxins and drugs
CA2489004C (en) 2002-06-13 2013-01-08 Crucell Holland B.V. Agonistic binding molecules to the human ox40 receptor
BRPI0613361A2 (pt) * 2005-07-01 2011-01-04 Medarex Inc anticorpo monoclonal humano isolado, composição, imunoconjugado, molécula biespecìfica, molécula de ácido nucleico isolada, vetor de expressão, célula hospedeira, camundongo transgênico, método para modular uma resposta imune num indivìduo, método para inibir crescimento de células tumorais num indivìduo, método para tratar uma doença infecciosa num indivìduo, método para aumentar uma resposta imune a um antìgeno num indivìduo, método para tratar ou prevenir uma doença inflamatória num indivìduo e método para preparar o anticorpo anti-pd-l1
EP3239178A1 (en) 2007-12-14 2017-11-01 Bristol-Myers Squibb Company Binding molecules to the human ox40 receptor
CN103221427B (zh) 2010-08-23 2016-08-24 德克萨斯州立大学董事会 抗ox40抗体和使用其的方法
GB201116092D0 (en) * 2011-09-16 2011-11-02 Bioceros B V Antibodies and uses thereof
US9856320B2 (en) 2012-05-15 2018-01-02 Bristol-Myers Squibb Company Cancer immunotherapy by disrupting PD-1/PD-L1 signaling
WO2013181634A2 (en) * 2012-05-31 2013-12-05 Sorrento Therapeutics Inc. Antigen binding proteins that bind pd-l1
PE20211291A1 (es) * 2014-03-31 2021-07-20 Genentech Inc Anticuerpos anti-ox40 y metodos de uso
SG11201608106PA (en) * 2014-03-31 2016-10-28 Genentech Inc Combination therapy comprising anti-angiogenesis agents and ox40 binding agonists
TW201619200A (zh) * 2014-10-10 2016-06-01 麥迪紐有限責任公司 人類化抗－ｏｘ４０抗體及其用途
WO2016081384A1 (en) * 2014-11-17 2016-05-26 Genentech, Inc. Combination therapy comprising ox40 binding agonists and pd-1 axis binding antagonists
KR20170108946A (ko) * 2014-12-05 2017-09-27 메모리얼 슬로안-케터링 캔서 센터 Fc 수용체-유사 5를 표적화하는 키메라 항원 수용체 및 그의 용도
US20180147271A1 (en) 2015-05-18 2018-05-31 Bluebird Bio, Inc. Anti-ror1 chimeric antigen receptors
WO2017068181A1 (en) * 2015-10-23 2017-04-27 Apogenix Ag Single-chain ox40-receptor agonist proteins
GB201519481D0 (en) 2015-11-04 2015-12-16 Cancer Rec Tech Ltd Immunomodulatory antibodies
WO2017087547A1 (en) * 2015-11-17 2017-05-26 Oncomed Pharmaceuticals, Inc. Pd-l1-binding agents and uses thereof
BR112018011336A2 (pt) * 2015-12-04 2018-12-04 Memorial Sloan-Kettering Cancer Center anticorpo anti-fcrl5 isolado ou um fragmento de ligação ao antígeno do mesmo, anticorpo scfv anti-fcrl5 isolado, anticorpo isolado ou porção de ligação ao antígeno do mesmo, composição, imunoconjugado, molécula biespecífica, ácido nucleico isolado, vetor de expressão, célula hospedeira, método para detectar fcrl5 em uma célula ou tecido inteiro, método para tratar câncer em um indivíduo, uso do anticorpo ou fragmento de ligação ao antígeno do mesmo, kit para tratar câncer
WO2017123673A2 (en) 2016-01-11 2017-07-20 Inhibrx Lp Multivalent and multispecific ox40-binding fusion proteins
US20190112380A1 (en) 2016-03-29 2019-04-18 University Of Southern California Chimeric antigen receptors targeting cancer
AR108377A1 (es) 2016-05-06 2018-08-15 Medimmune Llc Proteínas de unión biespecíficas y sus usos
KR102469248B1 (ko) 2018-02-28 2022-11-22 에이피 바이오사이언시스, 아이엔씨. 표적치료법을 위한 체크포인트 억제력을 갖는 이중작용성 단백질
WO2019184909A1 (zh) * 2018-03-27 2019-10-03 信达生物制药(苏州)有限公司 新型抗体分子、其制备方法及其用途

Also Published As

Publication number Publication date
CN118047873A (zh) 2024-05-17
CA3082036A1 (en) 2019-07-04
KR102452246B1 (ko) 2022-10-12
EP3731875A4 (en) 2021-12-08
EP3731875B1 (en) 2023-10-04
NZ763957A (en) 2023-10-27
CN111344019B (zh) 2024-03-15
TWI742336B (zh) 2021-10-11
JP2022109934A (ja) 2022-07-28
US11643470B2 (en) 2023-05-09
JP2021509258A (ja) 2021-03-25
MY195411A (en) 2023-01-19
TW202116811A (zh) 2021-05-01
ES2966569T3 (es) 2024-04-23
CN111344019A (zh) 2020-06-26
KR20200061397A (ko) 2020-06-02
US20230322939A1 (en) 2023-10-12
RU2020120518A (ru) 2022-01-31
EP4268848A3 (en) 2024-01-10
BR112020013133A2 (pt) 2020-12-08
TW201932486A (zh) 2019-08-16
AU2018394939A1 (en) 2020-05-14
AU2018394939B2 (en) 2022-02-24
EP4268848A2 (en) 2023-11-01
RU2020120518A3 (ko) 2022-01-31
JP7362614B2 (ja) 2023-10-17
US20200270357A1 (en) 2020-08-27
EP3731875A1 (en) 2020-11-04
WO2019133817A1 (en) 2019-07-04

Similar Documents

Publication Publication Date Title
IL290496A (en) Therapeutic antibodies and their uses
HK1257730A1 (zh) 抗despr單克隆抗體用於癌症和中風的靶向療法及成像
HRP20181802T1 (hr) Protutijela koja vežu humani cd3
IL267804A (en) Methods for treating cancer with anti-pd-1 antibodies
HK1245134A1 (zh) 用抗lap單克隆抗體治療癌症
EP3377102C0 (en) ANTI-PD-1 ANTIBODIES AND THEIR THERAPEUTIC USES
SG11202003893UA (en) Monospecific and bispecific proteins with immune checkpoint regulation for cancer therapy
IL248511A0 (en) Combined therapy for the treatment of cancer with a focovirus expressing the antigen and a monoclonal antibody against tim-3
IL276303A (en) Methods of treating cancer with ANTI-PD-1 antibodies
HK1247091A1 (zh) 治療抗體及其用途
IL256000A (en) Quantifying her 2 protein for optimal cancer therapy
IL278862A (en) Monospecific and multispecific anti-TMEFF2 antibodies and uses thereof
IL289247A (en) Bispecific molecules block an immune checkpoint
HUE053128T2 (hu) Bispecifikus antitestek rák immunterápiában történõ alkalmazásra
SG11202005296SA (en) Combination therapy between anti-progastrin antibody and immunotherapy to treat cancer
IL273092A (en) HDAC suppressor in combination with immune checkpoint modulators for cancer treatment